Advances in Immuno-positron Emission Tomography: Antibodies for Molecular Imaging in Oncology

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2012 Sep 19

PMID 22987087

Citations 94

Authors

Scott M Knowles

Anna M Wu

Affiliations

Soon will be listed here.

Abstract

Identification of cancer cell-surface biomarkers and advances in antibody engineering have led to a sharp increase in the development of therapeutic antibodies. These same advances have led to a new generation of radiolabeled antibodies and antibody fragments that can be used as cancer-specific imaging agents, allowing quantitative imaging of cell-surface protein expression in vivo. Immuno-positron emission tomography (immunoPET) imaging with intact antibodies has shown success clinically in diagnosing and staging cancer. Engineered antibody fragments, such as diabodies, minibodies, and single-chain Fv (scFv) -Fc, have been successfully employed for immunoPET imaging of cancer cell-surface biomarkers in preclinical models and are poised to bring same-day imaging into clinical development. ImmunoPET can potentially provide a noninvasive approach for obtaining target-specific information useful for titrating doses for radioimmunotherapy, for patient risk stratification and selection of targeted therapies, for evaluating response to therapy, and for predicting adverse effects, thus contributing to the ongoing development of personalized cancer treatment.

Citing Articles

Single-Chain Variable Fragments: Targeting Snake Venom Phospholipase A and Serine Protease.

Jia Y, Garcia A, Reyes E Toxins (Basel). 2025; 17(2).

PMID: 39998072 PMC: 11860530. DOI: 10.3390/toxins17020055.

Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.

Liu Y, Huang W, Saladin R, Hsu J, Cai W, Kang L Mol Pharm. 2024; 21(12):5909-5928.

PMID: 39537365 PMC: 11832138. DOI: 10.1021/acs.molpharmaceut.4c00848.

Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.

Volta L, Myburgh R, Pellegrino C, Koch C, Maurer M, Manfredi F Leukemia. 2024; 38(12):2598-2613.

PMID: 39294295 PMC: 11588662. DOI: 10.1038/s41375-024-02409-1.

Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer.

Parent E, Gleba J, Knight J, Kenderian S, Copland 3rd J, Cai H Mol Imaging Biol. 2024; 26(5):847-857.

PMID: 39174789 DOI: 10.1007/s11307-024-01945-7.

Engineered Antibodies as Cancer Radiotheranostics.

Wei Z, Li B, Wen X, Jakobsson V, Liu P, Chen X Adv Sci (Weinh). 2024; 11(30):e2402361.

PMID: 38874523 PMC: 11321656. DOI: 10.1002/advs.202402361.

References

Tijink B, Neri D, Leemans C, Budde M, Dinkelborg L, Stigter-van Walsum M . Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006; 47(7):1127-35. View

Mumprecht V, Honer M, Vigl B, Proulx S, Trachsel E, Kaspar M . In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res. 2010; 70(21):8842-51. PMC: 3398152. DOI: 10.1158/0008-5472.CAN-10-0896. View

Walrand S, Flux G, Konijnenberg M, Valkema R, Krenning E, Lhommel R . Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?. Eur J Nucl Med Mol Imaging. 2011; 38 Suppl 1:S57-68. DOI: 10.1007/s00259-011-1771-7. View

Rahmim A, Zaidi H . PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008; 29(3):193-207. DOI: 10.1097/MNM.0b013e3282f3a515. View

Pfaffen S, Frey K, Stutz I, Roesli C, Neri D . Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3. Eur J Nucl Med Mol Imaging. 2010; 37(8):1559-65. DOI: 10.1007/s00259-010-1446-9. View

Wright Jr G, Grob B, Haley C, Grossman K, Newhall K, Petrylak D . Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996; 48(2):326-34. DOI: 10.1016/s0090-4295(96)00184-7. View

Nayak T, Brechbiel M . Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem. 2009; 20(5):825-41. PMC: 3397469. DOI: 10.1021/bc800299f. View

Kashmiri S, Lee H, Milenic D, Poole D, Bernon E, Schlom J . A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm. 2000; 12(5):305-16. DOI: 10.1089/cbr.1997.12.305. View

Steeg P . Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program. Clin Cancer Res. 2008; 14(12):3643-5. PMC: 2692037. DOI: 10.1158/1078-0432.CCR-08-1135. View

10.

Pillay V, Gan H, Scott A . Antibodies in oncology. N Biotechnol. 2011; 28(5):518-29. DOI: 10.1016/j.nbt.2011.03.021. View

11.

Girgis M, Kenanova V, Olafsen T, McCabe K, Wu A, Tomlinson J . Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res. 2011; 170(2):169-78. DOI: 10.1016/j.jss.2011.03.065. View

12.

Olafsen T, Cheung C, Yazaki P, Li L, Sundaresan G, Gambhir S . Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel. 2004; 17(1):21-7. PMC: 4154813. DOI: 10.1093/protein/gzh009. View

13.

Shu L, Qi C, Schlom J, Kashmiri S . Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci U S A. 1993; 90(17):7995-9. PMC: 47274. DOI: 10.1073/pnas.90.17.7995. View

14.

Pentlow , Finn , Larson , Erdi , Beattie , Humm . Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. Clin Positron Imaging. 2000; 3(3):85-90. DOI: 10.1016/s1095-0397(00)00046-7. View

15.

Tolmachev V, Stone-Elander S . Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods. Biochim Biophys Acta. 2010; 1800(5):487-510. DOI: 10.1016/j.bbagen.2010.02.002. View

16.

Carlin S, Khan N, Ku T, Longo V, Larson S, Smith-Jones P . Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS One. 2010; 5(5):e10857. PMC: 2877709. DOI: 10.1371/journal.pone.0010857. View

17.

Nagengast W, de Korte M, Oude Munnink T, Timmer-Bosscha H, den Dunnen W, Hollema H . 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010; 51(5):761-7. DOI: 10.2967/jnumed.109.071043. View

18.

Buchegger F, Haskell C, Schreyer M, SCAZZIGA B, Randin S, Carrel S . Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med. 1983; 158(2):413-27. PMC: 2187333. DOI: 10.1084/jem.158.2.413. View

19.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

20.

Holland J, Divilov V, Bander N, Smith-Jones P, Larson S, Lewis J . 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010; 51(8):1293-300. PMC: 2998794. DOI: 10.2967/jnumed.110.076174. View